

Commissioner, FDCA, Gujarat - Dr. Hemant. G. Koshia inaugurates “Ortiv-Q3 – a SOTAX Joint Venture” in Ahmedabad

The Grand Inauguration of Ortiv-Q3 state-of-the-art Pharmaceutical Research and Analytical Laboratory in Ahmedabad took place on 10th October 2021.

MUMBAI, MAHARASHTRA, INDIA, October 14, 2021 /EINPresswire.com/ -- The newly inaugurated lab is located on Sarkhej Bavla Highway. Recently, SOTAX Group and Ortiv-Q3 had announced their collaboration, further strengthening their capabilities in the field of Pharma Services.

The inauguration took place at hands of Dr. Hemant. G. Koshia, Commissioner, Food and Drugs Control Administration Gujarat and in presence of Guest of Honour Rolf Benz, CEO and President of the Board of SOTAX Group.

The laboratory facility is spread over of ten thousand sqft. and is a new, state-of-the-art infrastructure including modern workspace and set of latest instruments to perform cGMP analytical services with a clear focus on complex dosage forms

characterization. The new infrastructure will facilitate accelerating complex formulation development program of global clients and shall work with a high throughput to perform excellent services to our customers. Soon the lab will be accredited by various regulatory agencies.



Dr. HG Koshia lighting the lamp



Dr. Hemant Koshia and Rolf Benz cutting the Ribbon

The new lab will offer various Routine Analytical Services (GMP) for QC and stability studies, Clinical and commercial batch release. Analytical Method Validation, Method Transfer. R&D Services like In Vitro Release Testing (IVRT, USP type 1-7), IVPT, Reverse Engineering, Q3 characterization (physico-chemical), API screening & impurities characterization. It would also support services like Troubleshooting & Investigations, Training, Consulting, Audits, Support for Q1/ Q2 regulatory clearance



Dr. Hemant Koshia and Rolf Benz unveiling Inauguration board

About SOTAX:

The SOTAX Group headquartered in Switzerland, is the leading global provider of complete testing solutions for Research and Development (R&D), Quality Control (QC), and In-Process Control (IPC) departments of the pharmaceutical industry. SOTAX's instruments, software, and services are recognized by their customers worldwide as the industry benchmark for best-in-class solutions. It is also the only analytical services supplier specialized in R&D for dissolution and release testing. The company is offering a high level of expertise for complex dosage forms testing as well as an FDA-inspected facility for routine cGMP testing. Its laboratories, located all over the globe, are operating for clients worldwide ranging from virtual companies to big Pharma including generic.

About Ortiv-Q3:

The Ortiv-Q3 company, founded by enthusiastic and experienced pharma professionals (Mukesh Kumar, Pawan Gupta and Ashish Gupta), provides a complete suite of drug release testing for a variety of dosage forms ranging from simple tablets to complex formulations like microspheres, suspensions, emulsions, nano-dispersions, liposomal and topical formulations. Also, Ortiv provides in-vitro permeation studies for topical and solid orals. The company is equipped with innovative and novel tools like micro dialysis and oral formulations permeation evaluation system, which can minimize the risk of bio-failures.

Dr. Prakash Bhosale

BBG EBRANDING MEDIA

+91 8097027355

press@bbgebranding.com

This press release can be viewed online at: <https://www.einpresswire.com/article/553814595>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.